Deck Bio to Present Multi-pMHC T Cell Engager Platform at the 8th T-Cell Engager Therapeutics Summit and BIO 2026

CAMBRIDGE, Mass., June 18, 2026 /PRNewswire/ -- Deck Bio, a biotechnology company advancing multi-pMHC targeted T cell engagers for solid tumors, today announced its participation in the 8th T-Cell Engager Therapeutics Summit and the BIO International Convention 2026, both taking place in...